MYGNMyriad Genetics, Inc.
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 107.1 vs a 23.6 median over 12 quarters (+353% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What MYGN's price assumes
Myriad Genetics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.67× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.78
Price / book · as of 2026-Q2
- EV / sales
- 0.68
EV / sales
Details›
- Price / bookas of 2026-Q2
- 1.78
- EV / EBIToperating margin −12%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 0.68
- Market capitalisation95.6 million shares, counted Jul 28, 2026
- $557M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #16 of 21 by RyuScore